Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

43pages

Published Date: January 2013

Published By: GBI Research

Category: Pharmaceutical
Description


Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

Summary

Leading business intelligence provider GBI Research has released its latest research report, entitled “Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market”. The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics. As a result, most patient populations experiencing more severe levels of pain across most pain indications, with the exception of, for example, migraines, are heavily dominated by opioids. As a therapeutic drug class, opioids have virtually no competition from molecules with non-opioid receptor targets. However, although the competition is virtually exclusively limited to opioid compounds, the current environment within this therapeutic class is highly competitive and strongly diversified. The approved drugs are based on 16 different opioid compounds and are differentiated on a range of characteristics, which include dosage, route of administration and pharmacokinetic features, as well as increasingly on the basis of abuse-resistance technologies. 

Whilst the prescription rates of opioid analgesic have seen a historically unprecedented increase over the last two decades, particularly in the US, this has resulted in a dramatic concomitant increase in opioid abuse and dependency. Over the last few years, the growing concern over opioid abuse has resulted in tighter regulations and increasingly vocal concerns by physicians. Due to these concerns from regulatory authorities and physicians about growing opioid abuse, there has been a seismic shift towards developing abuse-resistant formulations of extended-release opioid analgesics, including both novel products and reformulations of existing ones. Since the launch of the first abuse-resistant product, Embeda, in 2009, a whole range of novel products and reformulations of existing product ranges have been brought to the market. While abuse-resistant formulations do not confer any clinical benefits, they have become an essential differentiating factor in the current market environment in order ensure that products remain competitive for the future. There is a growing concentration and competition among abuse-resistant products, which is expected to be the primary driving factor in this largely stagnant market, particularly as the current developmental pipeline is very small and is characterized by a lack of innovation, with virtually no novel compounds and strong saturation across multiple pain indications.

Scope

  • An overview of the current opioid product market. 
  • A brief discussion about the inconsistent prescription preferences among European physicians.
  • A brief profile of the most important opioid products.
  • A pipeline analysis of the opioid products currently in development and an overview of the developmental pipeline by phase, by the route of administration and a summary of the promising pipeline products.  
  • An overview of the M&A and licensing deals, as well as co-development deals, across multiple indications in which opioids are frequently used in patients suffering from moderate to severe pain.

Reasons to buy

  • Identify trends in the developmental pipeline for opioid analgesics. 
  • Develop their awareness of the regulatory environment, physician concerns and inconsistency of prescription preferences among physicians.

 

 

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Introduction 7
2.1.1 High Levels of Product Diversification in a Highly Competitive Market Environment 7
2.1.2 Inconsistent Clinician Prescribing Preferences 7
2.1.3 Ongoing Market Shift Towards Abuse-Resistant Product Formulations 8
2.1.4 Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse 9
2.1.5 Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited 9

3 Overview of Currently Marketed Products 10
3.1 Major Marketed Products 10
3.1.1 Oxycontin 10
3.1.2 Exalgo 10
3.1.3 Onsolis 10
3.1.4 Duragesic 11
3.1.5 Opana ER 11
3.1.6 Vicodin CR 11
3.1.7 Dolophine Hydrochloride 11
3.1.8 Oxecta 11
3.1.9 Actiq 12
3.1.10 Embeda 12
3.1.11 Kadian 12
3.1.12 Avinza 12
3.2 Market Drivers and Barriers 13
3.2.1 Drivers 14
3.2.2 Barriers 15

4 Pipeline Analysis 17
4.1 Introduction 17
4.2 Opioid Compounds in the Developmental Pipeline 20
4.3 Distribution by Route of Administration 23
4.4 Promising Pipeline Products 26
4.4.1 ARX-01, AcelRX Pharmaceuticals 26
4.4.2 ALO-02, Pfizer 26
4.4.3 Zohydro ER, Zogenix 26
4.4.4 ELI-216, Elite Pharmaceuticals 27
4.4.5 BEMA Buprenorphine 27
4.4.6 CEP-33237, Cephalon 27

5 Deals Analysis 28
5.1 Overview: 28
5.1.1 M&As by Year 28
5.1.2 M&As by Value 29
5.1.3 Major M&As 30
5.2 Licensing Agreements 33
5.2.1 Licensing Agreements by Year 33
5.2.2 Licensing Agreements by Value 34
5.2.3 Major Licensing Agreements 35
5.3 Co-Development Agreements 38
5.3.1 Deals by Year 38
5.3.2 Major Co-Development Deals 39

6 Appendix 40
6.1 Abbreviations 40
6.2 Bibliography 41
6.3 Research Methodology 41
6.3.1 Coverage 41
6.3.2 Secondary Research 42
6.3.3 Primary Research 42
6.3.4 Pipeline Analysis 42
6.3.5 Expert Panel Validation 42
6.4 Contact Us 43
6.5 Disclaimer 43


List Of Figures


Figure 1: Opioids Market, Drivers and Barriers, 2012 13
Figure 2: Opioids Market, Global, R&D Pipeline by Phase (%), 2012 17
Figure 3: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase III 20
Figure 4: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase II 21
Figure 5: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase I 22
Figure 6: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase III 23
Figure 7: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase II 24
Figure 8: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase I 25
Figure 9: Opioids Market, M&As by Year, 2005–2012 28
Figure 10: Opioids Market, M&As by Value ($m), 2005–2012 29
Figure 11: Opioids Market, Licensing Agreements by Year, 2005–2012 33
Figure 12: Opioids Market, Licensing Agreements by Value ($m), 2005–2012 34
Figure 13: Opioids Market, Co-Development Agreements by Year, 2005–2012 38


List Of Tables


Table 1: Opioids Market, Global, R&D Pipeline Analysis by Phase, 2012 18

More Reports in





» Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

GBI Research, the leading business intelligence provider, has released its latest research: ‘Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting ’, which provides in-depth insights into the indication. It gives an estimation of market size fo...


» Market Snapshot: Mammography Systems 2006 to 2020 - Americas (US, Canada, Brazil, Mexico)

GBI Research’s report, “Market Snapshot: Mammography Systems 2006 to 2020 Americas (US, Canada, Brazil, Mexico)” provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume ov...


» Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeut...


» Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe

GBI Research’s report: “Transcatheter Heart Valve 2007 to 2020 – Europe” provides quantitative analysis of the transcatheter heart valves market in Europe. The analysis includes market size data by revenue and volume over the 2007–2020 period and key company share data by revenue in 2013 for the following countries...


» Ventilators Market to 2020 - Technical Advances and Hospital Expansion Serve as Distinct Regional Growth Drivers

Ventilators Market to 2020” discusses the market, competitive landscape, and trends for three ventilator market segments: Adult/pediatric, neonatal and transport ventilators. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews t...


» Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market”. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to incre...


» Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy...


» Market Snapshot: Transcatheter Heart Valves 2007 to 2020 - Americas

GBI Research’s report: “Transcatheter Heart Valves 2007 to 2020 – Americas” provides quantitative analysis of the transcatheter heart valves market in Americas. The analysis includes market size data by revenue and volume over the 2007–2020 period and key company share data by revenue in 2013 for the following...


» Market Snapshot: Mammography Systems 2006 to 2020 - Europe (Germany, UK, France, Italy, Spain)

GBI Research’s report, “Market Snapshot: Mammography Systems 2006 to 2020 - Europe (Germany, UK, France, Italy, Spain)” provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and vo...


» Market Snapshot: Glucose Monitoring Devices 2006 to 2020 - Benelux and Scandinavia (Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway)

Market Snapshot: Glucose Monitoring Devices 2006 to 2020 Benelux and Scandinavia (Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway)” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and vol...



Related News

News Aug 10, 2012

Theranostics Imaging Offers Means of Killing Prostate Cancer Cells without Harming Other Healthy Cells

Cancer imaging experts at John Hopkins Cancer Research Center claimed that they have developed a method for finding and killing malignant cells and sparing the healthy ones. The study was conducted on human prostate cancer cells and mice. The met...

News Oct 29, 2012

The Pharmaceutical Industry And Research

In a world in economic crisis, perhaps still unpredictable consequences in terms of its magnitude and duration, we can reflect on the possible consequences of the crisis may have on the pharmaceutical industry, especially its research and develop...

News Oct 9, 2012

A Donation fund for Pharmaceutical Research

The World Health Organization is planning a Kyoto Protocol for health. States should pay research funds to fight neglected diseases worldwide. To lofty goals lacks the World Health Organization (WHO) does not: It plans with the interests ...

News Oct 10, 2012

Allergy to Cold - Symptoms, Treatment and Tips for Everyday Life

Normally enough warm clothing to defy low outdoor temperatures. Who but suffers from an allergy to cold, has much bigger problems to deal with than "just" cold hands and feet. What is an allergy to cold and how it expresses itself ? ...

News Oct 10, 2012

Healthy Grilling Pleasure

More and more people flock to the park to enjoy the sun. And the barbecue season begins slowly: Instead of greasy sausages and potato salad with mayonnaise, we give you tips for calorie conscious and healthy grilling pleasure. Tonigh...

News Oct 10, 2012

Relaxation on Holiday - but how?

Can the earned annual leave to compensate for the hard work of the rest of the year? We need regular timeouts for regeneration? The recreation research has revealed new aspects. Secured is more important than a good holiday exchange of tension an...

News Oct 10, 2012

Stress and stress that: 7.Stress and Burnout

Everyone knows states of exhaustion - if we have spent ourselves, physically sleep after a long run or mentally after an examination or a combination of both, for example, after a long day at work or when the kids are finally in bed at night...

News Oct 10, 2012

Top 10 Tips for Losing Weight

We summarize now the top 10 tips for losing weight together: They are simple and feasible for anyone who wants to lose weight healthy. A tip from the start: Sets not all weight loss tips to and steps at once, otherwise it will be too much at once...

News Oct 10, 2012

What to do about Anorexia at the Age?

Many people who care for your children at home, the problem: In old age, many people to anorexia. To overcome this, you can use various tricks. First, it helps the members with recipes that they delight to know from your childhood. Especially wit...


All Rights Reserved   Latest News   Latest Reports